The purpose of this study is to see if giving an investigational drug called DN24-02 after surgery for urothelial cancers (those of the bladder, renal pelvis, ureter, or urethra) helps patients live longer. DN24-02 works by boosting the power of the immune system against the cancer by recognizing a protein on some tumor cells called HER2/neu.
Patients will be randomly assigned to receive DN24-02 or not. Those who do not receive the study drug will undergo periodic assessment with their doctors.
Patients who receive DN24-02 will have some of their white blood cells removed through a process called leukapheresis. The white blood cells are mixed in the laboratory with DN24-02 and then returned to the patient. The modified white blood cells recognize HER2/neu and prompt the immune system to identify and kill cancer cells.